patients. Median duration to recurrence after resection was 312 days (95% confidence interval [CI], 260–364 days).

Assessment of Initial Recurrence

Initial recurrence was diagnosed based on cytology in 4 patients and CT in 69 patients. Cytology revealed the presence of IDC of the pancreas in ascites of 2 patients and pleural effusion in 2 patients, and date of initial recurrence date was determined as the puncture date on the basis of cytology reports. Computed tomography was performed using a helical CT scanner (X-Vigor Laudator; Toshiba Medical, Tokyo, Japan). All helical CT scans were performed concomitantly with dynamic studies. Tumor recurrence on CT examination was defined as abnormal and/or increasing tissue or nodules depicted in the portal phase scanned 60 to 70 seconds after the start of contrast media administration. Date of initial recurrence was determined as the day when CT examination contributing to the confirmed diagnosis of the recurrence was performed. One author (S.M.) reviewed all CT reports and images and evaluated CT findings. According to CT review, 43 patients displayed local recurrence defined as locoregional recurrence, including lymph node metastases, 39 patients had hepatic metastases, and 10 patients showed peritoneal dissemination diagnosed as metastatic peritoneal nodules.

Clinical Parameters

The following clinical parameters at initial recurrence were evaluated (Table 1): (1) age; (2) sex; (3) operative method; (4) Eastern Cooperative Oncology Group performance status (PS)[8]; (5) weight loss ratio, calculated as (100 × [body weight at initial operation − body weight at recurrent]/body weight at initial operation); (6) blood level of hemoglobin (Hgb); (7) blood platelet count (Plt); (8) serum level of total bilirubin (T.Bil); (9) serum level of albumin (Alb); (10) serum level of total cholesterol (T.cho); (11) serum level of pseudo-cholinesterase (ChE); (12) serum level of carcinoembryonic antigen (CEA); (13) serum level of carbohydrate antigen (CA) 19-9; (14) ascites confirmed on CT; and (15) site of initial recurrence. These 15 parameters were classified to 2 or more categories according to usual status, mean value, or reported values, as quoted from reports by Scott et al,[9] Gianotti et al,[2] and Tas et al,[3] National Cancer Institution–Common Toxicity Criteria (NCI-CTC) version 2.0,[10] and Child classification[11] for analysis of clinical prognostic factors (summarized in Table 2). All clinical data were obtained within 2 weeks from date of initial recurrence.

Histological Parameters

The only material appropriate for evaluating histological findings as to the invasiveness of the entire tumor is from primary tumor in pancreatic IDC because surgical treatment for metastatic or recurrent pancreatic IDC is not usually performed. The resected specimen of primary pancreatic IDC was thus evaluated histologically. Methods of the histological examination have been described in our previous report.[7] Briefly, pathological diagnosis and findings were evaluated and confirmed by 2 authors (S.M. and T.H.). Pathological parameters were categorized as follows: (1) tumor size (≤3.0 or >3.0 cm), (2) predominant differentiation of tumor (well/moderately or poorly differentiated), (3) least differentiation of tumor (well/moderately or poorly differentiated), (4) retroperitoneal invasion (0/1 or 2/3), (5) lymphatic invasion (0/1 or 2/3), (6) vascular invasion (0/1 or 2/3), (7) intrapancreatic neural invasion (0/1 or 2/3), (8) Japanese pathological N category (JpN) (JpN0/1/2 or JpN3),[12] (9) International Union Against Cancer (UICC) pathological T category (pT) (pT1/2 or pT3),[13] (10) UICC pathological stage (UICC pStage; IA/IB/IIA or IIB/IV),[13] (11) tumor necrosis (absent or present),[7] (12) nerve plexus invasion (absent or present), (13) fibrotic focus (absent or present),[7] (14) UICC pathological N category (pN) (pN0 or pN1),[13] and (15) UICC R classification (R0 or R1).[13] The above categorizations of 15 pathological factors reflected prognostic impact in our previous study.[7] Predominant and least differentiation were estimated according to World Health Organization classifications.[14] Retroperitoneal invasion, lymphatic invasion, vascular invasion, and intrapancreatic neural invasion were classified into 0, 1, 2, and 3 according to the following: 0, not observed; 1, slightly seen; 2, occasionally seen; and 3, frequently seen.

TABLE 1. Patient Characteristics at Initial Recurrence After Curative Resection for IDC of the Pancreas

Age (median/range), yrs	62/25–81
Sex (male/female), n	41/32
Operation (PD/DP), n	55/18
PS (0/1/2/3), n	5/33/19/16
Ascites (absent/present), n	50/23
Weight loss ratio (mean [95% CI]), %	5.8 (3.3–8.3)
Hgb (mean [95% CI]), g/dL	11.1 (10.6–11.5)
Plate (mean [95% CI]), $\times 10^4$/dL	21.3 (19.0–23.6)
T.Bil (mean [95% CI]), mg/dL	0.9 (0.7–1.2)
Alb (mean [95% CI]), g/dL	3.5 (3.4–3.6)
T.cho (mean [95% CI]), IU/mL	150.2 (140.6–160.0)
ChE (mean [95% CI]), IU/dL	205.0 (188.8–221.3)
CEA (mean [95% CI]), ng/mL	38.3 (14.2–62.4)
CA19-9 (mean [95% CI]), U/mL	2945.5 (570.3–5320.8)
Duration to recurrence (d)	311.7 (259.5–363.9)
Diagnostic modality for recurrence (n)	
CT	69
Cytology	4
Initial recurrent site (n)	
Local recurrence	43
Liver metastasis	39
Peritoneal dissemination	12
Initial therapy for recurrence (n)	
Chemotherapy	22
Radiotherapy	6
Resection	6
Palliative therapy	39

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation. Palliative therapy meant best support care, and the patients with palliative therapy did not receive any antitumor treatments.

Statistical Analysis

Survival was calculated from the date of initial recurrence. Median duration of follow-up was 1921 days (95% CI, 1670–2283 days). Parameters with 3 or more grades such

TABLE 2. Summary of Categories Tested to Determine Cutoffs for Predicting Prognosis in Each Clinical Parameter

Parameter	Tested Category	Reference for Tested Category
Age (yrs)	≤62, >62	Mean value
Sex	Male, female	
Operation	PD, DP	
PS	0, 0–1, 0–3, 1–2, 3	
Ascites	Absent, Present	
Weight loss ratio (%)	<0, 0 to <5, 5 to <10, ≥10	Gianotti et al,[2] Scott et al[9]
Hgb (g/dL)	<8.0, 8.0 to <10.0, 10.0 to <12.0, ≥12.0	Tas et al,[3] NCI-CTC version 2.0[10]
Plt ($\times 10^4$/dL)	<10.0, 10.0 to <15.0, 15.0 to <40.0, ≥40.0	NCI-CTC version 2.0[10]; upper limit of normal value; lower limit of normal value
T.Bil (mg/dL)	<1.2, 1.2 to <2.0, ≥2.0	Upper limit of normal value; Child classification[11]
Alb (g/dL)	<2.0, 2.0 to <3.0, 3.0 to <3.5, ≥3.5	NCI-CTC version 2.0[10]; Child classification[11]
T.cho (IU/mL)	<100, 100 to <150, 150 to <200, ≥200	Mean value; mean value ±50
ChE (IU/dL)	<150, 150 to <200, 200 to <250, >250	Mean value; mean value ±50
CEA (ng/mL)	<5, 5 to <10, 10 to <40, 40 to <100, ≥100	Upper limit of normal value; 2× upper limit of normal value; mean value; 100
CA19-9 (U/mL)	<38, 38 to <100, 100 to <500, 500 to <1000, 1000 to <3000, 3000 to <10,000, ≥10,000	Upper limit of normal value; mean value; 100; 500; 1000; 10,000
Duration to recurrence (d)	<180, ≥180	Mean value
Peritoneal dissemination	Absent, present	

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation.

as PS were classified into 2 groups according to the significant cutoff to assign patient survival data using the log-rank test (significant cutoff shown in Table 3). Clinical parameters that significantly associated with survival rates in univariate analyses were further analyzed together in multivariate analyses using the Cox proportional hazard regression model to identify independent clinical prognostic parameters. Survival curves were drawn using the Kaplan-Meier method. To investigate relationships between important clinical parameters and histological findings, the frequency of patients with each important clinical prognostic factor was calculated for each pathological parameter and evaluated using Fisher exact test. Noncategorical data were compared using a 2-tailed Student t test. Values of $P < 0.05$ were considered statistically significant. All analyses were performed using Statview-J 5.0 software, Windows version (SAS, Cary, NC).

TABLE 3. Univariate Analyses and Survival Outcome in Patients With Recurrence Who Underwent Curative Resection for IDC of the Pancreas

Parameter	Category	P
Age (yrs)	≤62/>62	0.859
Sex	Male/female	0.986
Operation	PD/DP	0.092
PS	0, 1/2, 3*	<0.001
Ascites	Absent/present*	0.002
Weight loss ratio (%)	<0/≥0	0.555
Hgb (g/dL)	<12.0*/≥12.0	0.004
Plt ($\times 10^4$/dL)	<10.0*/>10.0	0.015
T.Bil (mg/dL)	<1.2/≥1.2*	0.031
Alb (g/dL)	<3.5*/≥3.5	0.003
T.cho (IU/mL)	<150*/≥150	0.013
ChE (IU/dL)	<200*/≥200	<0.001
CEA (ng/mL)	<40/≥40*	<0.001
CA19-9 (U/mL)	<100/≥100*	0.003
Duration to recurrence (d)	<180/>180	0.515
Peritoneal dissemination	Absent/present*	<0.001

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation.

*Factor displayed significant prognostic impact in univariate analysis and was used for multivariate analysis in Table 4. Univariate analysis was performed using the log-rank test. Level of significance was set at $P < 0.05$.

RESULTS

Patient Characteristics

Clinical data for 73 pancreatic IDC patients at initial recurrence are summarized in Table 1. Performance status 3 was present in 22% of patients. Weight loss was observed in 77% of patients, and mean weight loss ratio was 5.8%. No obvious jaundice was observed, and mean T.Bil was 0.9 mg/dL. Local recurrence, liver metastasis, and peritoneal dissemination were identified in 43, 39, and 12 patients, respectively. Chemotherapy (30%) and palliation (53%) were mainly chosen for the treatment of initial recurrence.

Survival and Prognostic Factors

The cumulative survival curve after initial recurrence is shown in Figure 1A. Median survival time and 1-year cumulative survival rate were 140 days and 22%, respectively. Univariate analysis produced the following candidates for predicting prognosis: PS, ascites, Hgb, Plt, T.Bil, Alb, ChE, CEA, CA19-9, and peritoneal dissemination (Table 3). Multivariate analysis (Table 4) revealed the following independent prognostic factors: PS, 2 or 3 (n = 35; hazard ratio [HR], 2.2; $P = 0.007$); ChE less than 200 IU/dL (n = 35; HR, 3.2; $P < 0.001$) (Fig. 1B); CEA, 40 ng/mL or greater (n = 10; HR, 2.7; $P = 0.026$); CA19-9 greater than 100 U/mL



FIGURE 1. Survival curves after initial recurrence. A, Survival curve for all patients. B, Survival curve assigned by serum ChE level. Prognosis was significantly worse in patients with low ChE than in those with high ChE levels. C, Survival curve assigned by serum CA19-9 level. Survival was significantly shorter in patients with high CA19-9 than in those with low CA19-9 levels. Values of $P < 0.05$ were considered statistically significant.

TABLE 4. Multivariate Analyses in Patients With Recurrence Who Underwent Curative Resection for IDC of the Pancreas

Parameter	Tested Factor	N	HR	95% CI	P
PS	2,3	35	2.2	1.2–3.9	0.007
ChE (IU/dL)	<200	35	3.2	1.7–6.1	<0.001
CEA (ng/mL)	≥40	10	2.7	1.1–6.4	0.026
CA19-9 (U/mL)	≥100	52	1.9	1.0–3.6	0.038
Peritoneal dissemination	Present	12	5.0	2.1–11.6	<0.001
Group without peritoneal dissemination					
ChE (IU/dL)	<200	26	3.5	1.8–6.9	<0.001
CA19-9 (U/mL)	≥100	44	2.8	1.4–5.5	0.003

Multivariate analysis was performed using the Cox hazard regression model. Level of significance was set at $P < 0.05$.

(n = 52; HR, 1.9; $P = 0.038$) (Fig. 1C); and peritoneal dissemination (n = 12; HR, 5.0; $P < 0.001$). Peritoneal dissemination is a parameter predictive of poor prognosis in general, and prognostic factors in patients without peritoneal dissemination are also important. Additional multivariate analysis was therefore performed in patients without peritoneal dissemination, demonstrating that ChE less than 200 IU/dL (n = 26; HR, 3.5; $P < 0.001$) and CA19-9 100 U/mL or greater (n = 44; HR, 2.8; $P = 0.003$) showed independent prognostic value from peritoneal dissemination (Table 4).

Correlation Between Clinical Parameters and Histological Findings

Patients showing nerve plexus invasion in primary tumors displayed ChE less than 200 IU/dL (65% vs 35%; $P = 0.031$) and CA 19-9 100 U/mL or greater (74% vs 26%; $P = 0.003$) at initial recurrence significantly more frequently than patients without plexus invasion (Table 5). No other histological factors showed significant associations with ChE and CA19-9. Furthermore, patients with nerve plexus invasion showed significantly lower ChE levels than patients without nerve plexus invasion (mean, 180 vs 219 IU/dL; $P = 0.023$; Table 6), but CA19-9 levels did not differ significantly between patients with and without nerve plexus invasion (mean, 2166 vs 3377 U/dL; $P = 0.630$; Table 6). In the view of other clinical data, the patients with nerve plexus invasion in primary tumor showed anemia significantly ($P = 0.030$; Table 6). On the basis of these results, only nerve plexus invasion as a histological factor of primary tumor correlated with the important clinical factor of ChE at initial recurrence.

Clinical Characteristics of Patients With Lower ChE

To identify patient characteristics associated with ChE less than 200 IU/dL, clinical data were compared between patients with serum ChE level at initial recurrence less than 200 or greater than or equal to 200 IU/dL (Table 7). Surprisingly, patients with ChE less than 200 IU/dL showed significant cachexia compared with patients with ChE 200 IU/dL or greater as follows: poor performance status (mean PS, 2.1 vs 1.2; $P < 0.001$), anemia (mean Hgb, 10.2 vs 11.9 g/dL; $P < 0.001$), hypoalbuminemia (mean Alb, 3.1 vs 3.9; $P < 0.001$), hypocholesterolemia (mean T.cho, 125.4 vs

TABLE 5. Correlation Between Pathological Factors and Independent Clinical Prognostic Factors in Patients With Recurrence After Curative Resection for IDC of the Pancreas

Pathological Parameter	Category	CA19-9 (U/mL)			ChE (IU/dL)		
		<100	≥100	P	<200	≥200	P
Tumor size (cm)	≤3.0/>3.0	12/9	21/31	0.207	15/20	18/20	0.815
Predominant differentiation	Well, mod/poor	16/5	48/4	0.109	31/4	33/5	>0.999
Least differentiation	Well, mod/poor	12/9	27/25	0.797	21/14	18/20	0.350
Retroperitoneal invasion	0, 1/2, 3	5/16	25/27	0.069	13/22	17/21	0.635
Lymph vessel invasion	0, 1/2, 3	15/6	39/13	0.774	25/10	29/9	0.790
Blood vessel invasion	0, 1/2, 3	2/19	6/46	>0.999	6/29	2/36	0.142
Intrapancreatic neural invasion	0, 1/2, 3	5/16	15/37	0.777	9/26	11/27	0.798
Nerve plexus invasion	Absent/present	19/2	28/24	0.003	18/17	29/9	0.031
JpN	JpN0, 1/JpN2, 3	16/5	39/13	>0.999	25/10	30/8	0.588
UICC pT	1, 2/3	2/19	2/50	0.574	0/35	4/34	0.116
UICC pN	0/1	2/19	9/43	0.494	4/31	7/31	0.519
UICC pStage	≤IIA/≥IIB	1/20	8/44	0.432	3/32	6/32	0.483
UICC R	R0/R1	17/4	43/9	>0.999	29/6	31/7	>0.999
Tumor necrosis	Absent/present	14/7	33/19	>0.999	22/13	25/13	0.812
Fibrotic focus	Absent/present	8/13	21/31	>0.999	16/19	13/25	0.347

Categorical analysis was performed using Fisher exact test. Level of significance was set at $P < 0.05$.

JpN indicates classification of lymph node metastasis according to Japan Pancreas Society criteria; JpN0/JpN1/JpN2/JpN3, parameters showing the range of lymph node metastasis according to classifications of the Japanese Pancreas Society; mod, moderately differentiated; poor, poorly differentiated; UICC, classification according to International Union Against Cancer criteria; 0, none; 1, slightly seen; 2, occasionally seen; 3, frequently seen; well, well differentiated.

173.2 IU/mL), and ascites (70% vs 30%; $P = 0.025$) (Table 6). Elevation of bilirubin and a high frequency of liver metastasis were not associated with ChE less than 200 IU/dL.

Clinical and Histological Characteristics in Patients With Liver Metastasis

Serum ChE is synthesized in and released from the liver. The serum level of ChE may be affected by liver metastasis. To evaluate the association between serum ChE and liver metastasis, the distribution of clinical parameters at initial recurrence was analyzed according to the presence of liver metastasis (Table 8). Hepatic metastasis is common distant spreading manner of pancreatic cancer, and the associated histological factors with hepatic metastasis may be useful information for clinicians to predict clinical course and choose the treatment. Therefore, the distribution of histological findings of primary tumor was analyzed according to the presence of liver metastasis in addition (Table 8). Large tumor size ($P = 0.010$), poor differentiation on least differentiation of tumor ($P = 0.002$) and the presence of tumor necrosis

TABLE 6. Distribution of Clinical Parameters at Initial Recurrence According to the Presence of Nerve Plexus Invasion in Primary Tumor

Parameter	Category	Nerve Plexus Invasion in Primary Tumor		P
		Absent	Present	
PS	Mean (95% CI)	1.62 (1.39–1.86)	1.48 (1.0–1.9)	0.520
Hgb (g/dL)	Mean (95% CI)	11.5 (10.9–12.0)	10.4 (9.7–11.1)	0.030
Plt ($\times 10^4$/dL)	Mean (95% CI)	21.4 (18.6–24.2)	21.1 (17.1–25.1)	0.883
T.Bil (mg/dL)	Mean (95% CI)	1.0 (0.6–1.3)	0.8 (0.6–1.1)	0.645
Alb (g/dL)	Mean (95% CI)	3.6 (3.4–3.7)	3.4 (3.1–3.6)	0.216
T.cho (IU/mL)	Mean (95% CI)	152.9 (140.7–165.0)	145.5 (128.5–162.6)	0.473
ChE (IU/dL)	Mean (95% CI)	218.7 (197.9–239.5)	180.3 (155.6–205.0)	0.023
CEA (ng/mlL)	Mean (95% CI)	25.0 (2.5–47.6)	62.3 (6.7–117.9)	0.141
CA19-9 (U/mL)	Mean (95% CI)	3376.7 (−286.0 to 7039.3)	2166.1 (816.0–3516.3)	0.630
Weight loss ratio (%)	Mean (95% CI)	6.7 (4.1–9.4)	4.5 (−0.8 to 9.8)	0.403
Duration to recurrence (d)	Mean (95% CI)	330.6 (257.0–404.1)	277.6 (211.6–343.6)	0.336
Ascites (n)	Absent/present	33/14	17/9	0.794
Local recurrence (n)	Absent/present	22/25	8/18	0.220
Liver metastasis (n)	Absent/present	23/24	11/15	0.631
Peritoneal dissemination (n)	Absent/present	40/7	21/5	0.744

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation. Analysis was performed using 2-tailed Student t test or Fisher exact test. Level of significance was set at $P < 0.05$.

TABLE 7. Patient Characteristics Classified According to Serum Cholinesterase Level

Parameter		ChE <200 (IU/dL)	ChE ≥200 (IU/dL)	P
PS	Mean (95% CI)	2.1 (1.7–2.4)	1.2 (1.0–1.5)	<0.001
Hgb (g/dL)	Mean (95% CI)	10.2 (9.5–10.9)	11.9 (11.5–12.4)	<0.001
Plt (×104/dL)	Mean (95% CI)	19.6 (16.0–23.2)	22.9 (20.1–25.7)	0.145
T.Bil (mg/dL)	Mean (95% CI)	1.1 (0.7–1.4)	0.8 (0.4–1.1)	0.235
Alb (g/dL)	Mean (95% CI)	3.1 (2.9–3.2)	3.9 (3.8–4.0)	<0.001
T.cho (IU/mL)	Mean (95% CI)	125.4 (113.8–137.0)	173.2 (161.9–184.5)	<0.001
ChE (IU/dL)	Mean (95% CI)	146.3 (135.8–156.8)	259.2 (243.4–275.0)	
CEA (ng/mL)	Mean (95% CI)	41.6 (9.0–74.1)	35.3 (−1.4 to 72.1)	0.798
CA19-9 (U/mL)	Mean (95% CI)	2639.6 (974.8–4304.3)	3227.3 (−1181.6 to 7636.3)	0.807
Weight loss ratio (%)	Mean (95% CI)	6.2 (2.0–10.4)	5.5 (2.2–8.9)	0.809
Duration to recurrence (d)	Mean (95% CI)	328.4 (247.9–408.9)	296.3 (225.6–367.1)	0.544
Ascites (n)	Absent/present	19/16	31/7	0.025
Local recurrence (n)	Absent/present	12/23	18/20	0.351
Liver metastasis (n)	Absent/present	19/16	15/23	0.168
Peritoneal dissemination (n)	Absent/present	26/9	35/3	0.065

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation. Analysis was performed using 2-tailed Student *t* test or Fisher exact test. Level of significance was set at $P < 0.05$.

($P = 0.015$) in histological findings of primary tumor and high serum CEA level ($P = 0.012$), and short duration to recurrence ($P = 0.004$) in clinical parameters of initial recurrence were significantly associated with the presence of liver metastasis. Serum ChE level was not affected by the presence of liver metastasis significantly.

DISCUSSION

Low serum level of ChE at initial recurrence after resection was identified as an important clinical prognostic factor of pancreatic IDC in this study. The prognostic impact of serum ChE level has been reported in patients with liver cirrhosis[15] and advanced solid cancer.[16] In the present study, the prognostic value of serum ChE level was identified through multivariate analysis using all patients. In further multivariate analysis using patients without peritoneal dissemination, serum ChE level maintained its prognostic value. The prognostic power of serum ChE level was thus validated through 2 multivariate analyses in this study. Cholinesterase is formed in the liver and released into plasma immediately after synthesis.[17] Serum ChE level shows good correlation to Child-Pugh score,[15] a superior index of liver function.[18] Low serum level of ChE is thus regarded as indicative of hepatic impairment.[15,17] Significant characteristics of patients with low serum level of ChE at initial recurrence were worsened PS, anemia, hypoalbuminemia, hypocholesterolemia, and the presence of ascites. Because low serum level of ChE is associated with low functional state of the liver,[15,17] hepatic impairment might result in hypoalbuminemia, hypocholesterolemia, and the presence of ascites. Worsened PS[1] and anemia[9] have been reported as prognostic factors in patients with advanced cancer and are prevalent in patients with cancer cachexia.[9,15] Hypoalbuminemia is also indicated as a characteristic of cancer cachexia.[15] Conversely, body weight loss is an important finding in cancer cachexia[15] and was not a significant finding in our patients with low serum levels of ChE. These data might mean that body weight loss seems subsequent to worsened PS, anemia, hypoalbuminemia, and low serum levels of ChE. If body weight loss is necessary to fulfil the criteria for cancer cachexia and appears in more advanced states of disease progression, this study might indicate serum levels of ChE as a sensitive marker of cancer cachexia. Cholinesterase and the associated factors with low serum ChE level, PS, Hgb, Alb, and T.cho are the index of malnutrition. Cholinesterase shows the strongest predictive power of prognosis in nutritional parameters. This result may indicate that life-threatened nutritional factor is a hepatic impairment that is well indexed by ChE. This hypothesis needs further clinical and experimental studies to evaluate liver function, hematogenesis, digestive absorption, and appetite in pancreatic cancer patients, to find the molecule resulting in abnormality of hepatocyte function, and to reveal ChE as the most sensitive marker to abnormal hepatocyte.

A significant correlation was identified between nerve plexus invasion by the primary tumor and low serum ChE level in this study. Nerve plexus invasion is a common behavior of primary pancreatic IDC and has been identified as an important prognostic factor in our own[7,19] and other studies.[20] When nerve plexus invasion at initial recurrence is mentioned, 2 important issues should be clarified: (1) the presence of nerve plexus invasion at initial recurrence and (2) alteration of tumor characteristics from primary tumor to tumor recurrence. First, whether nerve plexus invasion exists at initial recurrence after resection is important. According to recent reports, nerve plexus invasion is observed in 79% of autopsies for patients who died of recurrence after resection for pancreatic IDC.[21] Median survival after initial recurrence was 4.7 months in this study compared with 3 to 7 months in another study.[22] In the very short duration between initial recurrence and death, some discrepancies may exist between frequency of nerve invasion at autopsy and at initial recurrence. We thus suspect that nerve plexus invasion is prevalent at initial recurrence after resection, appearing in up to almost 80% of patients according to Hishinuma et al.[21]

TABLE 8. Distribution of Clinical and Histological Parameters According to the Presence of Liver Metastasis

Parameter	Category	Liver Metastasis at Initial Recurrence		P
		Absent	Present	
Histological in primary tumor				
Tumor size (cm)	<3.0/>3.0	21/13	12/27	0.010
Predominant differentiation	Well, mod/poor	32/2	32/7	0.162
Least differentiation	Well, mod/poor	25/9	14/25	0.002
Retroperitoneal invasion	0, 1/2, 3	13/21	17/22	0.812
Lymph vessel invasion	0, 1/2, 3	28/6	26/13	0.182
Blood vessel invasion	0, 1/2, 3	6/28	2/37	0.135
Intrapancreatic neural invasion	0, 1/2, 3	8/26	12/27	0.602
Nerve plexus invasion	Absent/present	23/11	24/15	0.631
JpN	JpN0, 1/JpN2, 3	24/10	31/8	0.424
UICC pT	pT1, 2/pT3	4/57	0/12	>0.999
UICC pN	pN0/pN1	5/29	6/33	>0.999
UICC pStage	<IIA/>IIB	4/30	5/34	>0.999
UICC R	R0/R1	28/6	32/7	>0.999
Tumor necrosis	Absent/present	27/7	20/19	0.015
Fibrotic focus	Absent/present	18/16	11/28	0.054
Clinical at initial recurrence				
PS	Mean (95% CI)	1.7 (1.3–2.0)	1.5 (1.2–1.8)	0.462
Hgb (g/dL)	Mean (95% CI)	11.1 (10.5–11.8)	11.1 (10.4–11.7)	0.921
Plt (×104/dL)	Mean (95% CI)	20.2 (16.4–24.0)	22.3 (19.5–25.1)	0.348
T.Bil (mg/dL)	Mean (95% CI)	1.1 (0.6–1.6)	0.8 (0.6–0.9)	0.261
Alb (g/dL)	Mean (95% CI)	3.5 (3.2–3.7)	3.6 (3.4–3.7)	0.463
T.cho (IU/mL)	Mean (95% CI)	144.3 (130.0–158.6)	155.5 (142.0–169.0)	0.251
ChE (IU/dL)	Mean (95% CI)	197.8 (175.6–220.0)	211.3 (187.1–235.6)	0.411
CEA (ng/mL)	Mean (95% CI)	6.1 (3.6–8.7)	66.4 (22.4–110.4)	0.012
CA19-9 (U/mL)	Mean (95% CI)	555.5 (−61.8 to 1172.8)	5029.1 (630.9–9427.3)	0.061
Weight loss ratio (%)	Mean (95% CI)	6.7 (2.4–11.2)	5.2 (2.0–8.3)	0.541
Duration to recurrence (d)	Mean (95% CI)	391.2 (312.2–470.2)	242.4 (177.9–307.0)	0.004
Ascites (n)	Absent/present	24/10	26/13	0.803

Weight loss ratio was calculated as 100 × (body weight at initial operation − body weight at recurrence)/body weight at initial operation. Analysis was performed using 2-tailed Student *t* test or Fisher exact test. Level of significance was set at $P < 0.05$.

JpN indicates classification of lymph node metastasis according to Japan Pancreas Society criteria; JpN0/JpN1/JpN2/JpN3, parameters showing the range of lymph node metastasis according to classifications of the Japanese Pancreas Society; mod, moderately differentiated; poor, poorly differentiated; UICC, classification according to International Union Against Cancer criteria; 0, none; 1, slightly seen; 2, occasionally seen; 3, frequently seen; well, well differentiated.

Another important problem that should be described is the alteration of tumor characteristics between primary and recurrent tumor. Tumor cells evolve through a process analogous to Darwinian natural selection aided by genetic instability, resulting in the acquisition of growth advantages, and clonal progression of selected tumor cells contributes to tumor development.[23] Primary pancreatic IDCs evolve until clinical recurrence and are expected to possess a high ability for nerve invasion at initial recurrence compared with that at resection. Patients with nerve plexus invasion in primary tumor might thus display more severe nerve invasion at initial recurrence compared with patients without nerve plexus invasion in primary tumor. On the basis of this context, a significant relationship may exist between severe nerve invasion and low functional state of the liver. Mechanisms underlying such a relationship are unknown. Anatomically, the pancreatic nerve plexus is a part of a neural network connecting the spine and abdominal organs, and this network innervates the liver.[24] Sympathetic and parasympathetic hepatic nerve reportedly regulate hepatocyte metabolism.[25] Carreno and Seelaender[26] showed that liver denervation led the reduction of liver noradrenergic nerve, hepatic noradrenalin, hepatocyte mitochondrial fatty acid transport capacity, and fatty acid oxidation. In the view of the above reports, it is possible that the modulated hepatic nerve by nerve invasion via neural network changes hepatocyte metabolism. Low serum ChE level may indicate abnormal hepatic metabolism itself or hepatocyte impairment due to chronic abnormal hepatic metabolism. Relationships between nerve invasion and alteration of hepatic function may be a good target for further study.

Patients with peritoneal dissemination in pancreatic IDC show extremely poor prognosis, and survival time is reportedly 30 days or less.[27] This study revealed peritoneal dissemination as an important prognostic factor through multivariate analysis using all patients. When multivariate analysis was performed using patients without peritoneal dissemination, independent prognostic factors were high serum level of CA19-9 and low serum level of ChE. Carbohydrate antigen 19-9 has been reported as an important prognostic factor in previous studies.[28,29] Although the frequency of

patients with high serum level of CA19-9 level was significantly higher in patients with nerve plexus invasion of the primary tumor, mean CA19-9 level of patients with nerve plexus invasion was not significantly higher than that of patients without nerve plexus invasion. Carbohydrate antigen 19-9 level at initial recurrence was thus not significantly associated with histological factors in the primary tumor.

In summary, this study found that (1) peritoneal dissemination, low serum levels of ChE, and high serum levels of CA19-9 are important prognostic factors at initial recurrence after macroscopic resection for pancreatic IDC; (2) patients with low serum levels of ChE show a cachexia-like systemic condition; and (3) nerve plexus invasion and low serum levels of ChE at initial recurrence are significantly associated. This study may indicate an association between nerve invasion and hepatic impairment, and such a relationship warrants further study.

REFERENCES

1. Barber MD, Barber MD, Ross JA, et al. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. *Nutr Cancer*. 1999;35:106–110.
2. Gianotti L, Braga M, Radaelli G, et al. Lack of improvement of prognostic performance of weight loss when combined with other parameters. *Nutrition*. 1995;11:12–16.
3. Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. *Am J Clin Oncol*. 2001;24:547–550.
4. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. *Cancer*. 1995;75:2613–2622.
5. Costamagna G, Pandolfi M. Endoscopic stenting for biliary and pancreatic malignancies. *J Clin Gastroenterol*. 2004;38:59–67.
6. Wehrmann T, Riphaus A, Frenz MB, et al. Endoscopic pancreatic duct stenting for relief of pancreatic cancer pain. *Eur J Gastroenterol Hepatol*. 2005;17:1395–1400.
7. Mitsunaga S, Hasebe T, Iwasaki M, et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. *Cancer Sci*. 2005;96:858–865.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5: 649–655.
9. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. *Lung Cancer*. 2003;40:295–299.
10. Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.0. CTEP Web site. Available at: http://ctep.info.nih.gov. Accessed January 15, 2007.
11. Child CG III. *The Liver and Portal Hypertension*. Philadelphia, PA: WB Saunders; 1964.
12. Japan Pancreas Society. *The Classification of Pancreatic Carcinoma*. 1st English ed. Tokyo, Japan: Kanehara; 1996.
13. Sobin HL, Wiitekind C. *TNM Classification of Malignant Tumors*. 6th ed. New York: Wiley-Liss; 2002.
14. Hamilton RS, Aaltonen AL. *World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System*. Lyon, France: IARC Press; 2000.
15. Garello E, Battista S, Bar F, et al. Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations. *Dig Dis Sci*. 1999;44:782–788.
16. Maltoni M, Pirovano M, Nanni O, et al. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. *J Pain Symptom Manage*. 1997;13: 1–9.
17. Brown SS, Kalow W, Pilz W, et al. The plasma cholinesterases: a new perspective. *Adv Clin Chem*. 1981;22:1–123.
18. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg*. 1973;60: 646–649.
19. Mitsunaga S, Hasebe T, Kinoshita T, et al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. *Am J Surg Pathol*. 2007;31:1636–1644.
20. Nakao A, Harada A, Nonami T, et al. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. *Pancreas*. 1996;12:357–361.
21. Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. *J Gastrointest Surg*. 2006;10:511–518.
22. Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. *World J Surg*. 1997;21: 195–200.
23. Devita VT, Hellman S, Rosenberg SA. *CANCER Principles and Practice of Oncology*. 7th ed. Tokyo, Japan: Lippincott Williams and Wilkins; 2004.
24. Carpenter MB, Sutin J. *Human Neuroanatomy*. 8th Japanese ed. Niigata, Japan: Nishimura Co., Ltd.; 1995.
25. Puschel GP. Control od hepatocyte metabolism by sympathetic and parasympathetic hepatic nerve. *Anat Rec A Discov Mol Cell Evol Biol*. 2004;280:854–867.
26. Carreno FR, Seelaender MCL. Liver denervation affects hepatocyte mitochondrial fatty acid transport capacity. *Cell Biochem Funct*. 2004;22:9–17.
27. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer*. 1989;63:364–367.
28. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. *Br J Cancer*. 2005;93:740–743.
29. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. *Br J Cancer*. 2003;89:1413–1417.

Journal of



Hepato-Biliary-Pancreatic Surgery

Springer

Volume 15 Number 4 2008

J Hepatobiliary Pancreat Surg (2008) 15:449–452
DOI 10.1007/s00534-007-1254-1

Journal of HBP Surgery

Autoimmune pancreatitis with multifocal lesions

Masatoshi Kajiwara[1], Motohiro Kojima[2], Masaru Konishi[1], Toshio Nakagohri[1], Shinichiro Takahashi[1], Naoto Gotohda[1], Takahiro Hasebe[3], Atsushi Ochiai[2], and Taira Kinoshita[1]

[1] Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
[2] Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan
[3] Surgical Pathology Section, Clinical Laboratory Division, National Cancer Center Hospital East, Chiba, Japan

Abstract
Two cases of a focal type of autoimmune pancreatitis (AIP) with distinct double mass lesions within the pancreas are described. In both patients, computed tomography (CT) showed localized pancreatic masses with delayed enhancement, and magnetic resonance cholangiopancreatography (MRCP) revealed localized stenoses of the main pancreatic duct (MPD) with mild upstream dilatation. Fluorodeoxyglucose positron emission tomography (FDG-PET) examination, performed in one patient, showed intense uptake concordant with tumors. Both patients received pancreatic resection with a presumptive diagnosis of pancreatic carcinoma. Histologic evaluation of the tumors showed marked lymphoplasmacytic infiltration and fibrosis around the large and medium pancreatic ducts, without any evidence of malignancy. Serum IgG4 concentration, measured postoperatively, was elevated in both patients. The characteristic morphological features of AIP are diffuse swelling of the pancreatic parenchyma and diffuse narrowing of the MPD. Recently, a focal type of AIP, which mimics pancreatic carcinoma, has been recognized. Considering the favorable response of AIP to steroid therapy, it is clinically important to differentiate the focal type of AIP from pancreatic carcinoma and to know that AIP sometimes exhibits multiple lesions within the pancreas.

Key words Autoimmune pancreatitis · Multifocal lesions · IgG4 staining

Introduction

Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis associated with an autoimmune inflammatory process.[1] Although diffuse swelling of the pancreatic parenchyma and diffuse irregular narrowing of the pancreatic duct system are morphologically characteristic of AIP, a focal type of this clinical entity has been recently recognized.[2-4]

The focal type of AIP exhibits a localized mass lesion in the pancreas, similar to pancreatic carcinoma, and it often exhibits obstructive jaundice,[5] which is also characteristic of pancreatic carcinoma, when the lesion involves the head of the pancreas. Consequently, some patients with these features have been subjected to surgical exploration with a presumed diagnosis of pancreatic carcinoma.[6] Considering that AIP shows a favorable response to steroid therapy, the differentiation of these two entities is clinically important.

Although patients with AIP sometimes show multifocal or skipped narrowing of the main pancreatic duct (MPD), there have been only a few cases of AIP with multifocal lesions.[7] In this report, we describe the clinical, radiological, and histopathological features of two patients with AIP who exhibited distinct double masses in the pancreas; the masses were resected on the suspicion of pancreatic carcinoma.

Case reports

Case 1

A 62-year-old male patient with mild epigastralgia was referred for further investigation of pancreatic masses. He had no medical history of autoimmune disease, but he had a history of hypertension. The results of laboratory examinations, including complete blood count, electrolytes, bilirubin, liver function tests, and pancreatic enzymes and tumor markers (carbohydrate antigen [CA] 19-9, and carcinoembryonic antigen [CEA]), were all within normal limits. Computed tomography (CT) showed irregular mass lesions in the head and body of the pancreas (Fig. 1a, b); the lesions were 30 mm and 25 mm in diameter, respectively. The tumors showed slight attenuation in the delayed phase with contrast

Offprint requests to: T. Kinoshita
Received: May 29, 2007 / Accepted: July 13, 2007



Fig. 1a–e. Case 1. Computed tomography (CT) revealed irregular mass lesions in the head (**a**) and body (**b**) of the pancreas (*arrowheads*); early phase. **c**, **d** Fluorodeoxyglucose positron emission tomography (FDG-PET) showed intense uptake in both lesions (*arrows*), and their standardized uptake values (SUVs) were 6.6 and 8.3, respectively. (**c**, head; **d**, body). **e** Magnetic resonance cholangiopancreatography (MRCP) revealed skipped stenoses in the main pancreatic duct (MPD) concordant with the tumors (head, *arrows*; body, *arrowheads*), and mild dilatation between the tumors and distally

medium. Fluorodeoxyglucose positron emission tomography (FDG-PET) showed intense uptake in both lesions, and their standardized uptake values (SUVs) were 6.6 and 8.3, respectively (Fig. 1c, d). Magnetic resonance cholangiopancreatography (MRCP) revealed skipped stenoses of the MPD, concordant with the tumors, and mild dilatation between the tumors and distally (Fig. 1e).

Case 2

A 64-year-old male patient without any symptoms or past medical history was admitted because of pancreatic masses that were picked up on a medical checkup. Laboratory tests showed slight elevation of blood glucose (126 mg/dl; normal, 69–104 mg/dl) and hepatic enzymes (aspartate aminotransferase, 41 IU/l [normal, 13–33 IU/l], alkaline aminotransferase, 75 IU/l [normal, 8–42 IU/l]). Dynamic CT showed two lesions, in the body and tail of the pancreas, 28 mm and 30 mm in diameter, respectively, and exhibited subtle delayed enhancement (Fig. 2a). MRCP revealed obstruction of the MPD in concordance with the tumors, and slight dilatation between the tumors (Fig. 2b).

The proximal lesions in both patients were considered to be pancreatic carcinomas because the finding of localized stenoses with upstream dilatation of the MPD was suggestive of pancreatic carcinoma. The distal lesions were deemed to be either obstructive pancreatitis demonstrating mass lesions because of severe inflammation, or other primary pancreatic carcinoma. In case 1, core needle biopsy of the tumor in the pancreatic body was performed during surgery, and this revealed parenchymal fibrosis and infiltration of inflammatory cells, including plasma cells, without any evidence of malignancy. Therefore, Whipple resection was performed to resect only the head lesion. In case 2, the patient received distal pancreatectomy.

The three resected tumors (case 1, head; case 2, body and tail) resembled each other on both macroscopic and microscopic examinations. On gross appearance, all cut surfaces of the tumors demonstrated swelling of the parenchyma, but the border between the tumor and the surrounding pancreatic tissue was unclear, while the existing lobular structure and narrowed MPD were clearly identified (Fig. 2c). Microscopic examination confirmed marked lymphoplasmacytic infiltration and fibrosis around the large and medium pancreatic ducts



Fig. 2a–e. Case 2. **a** CT showed two lesions, in the body and tail of the pancreas (*arrowheads*), and exhibited subtle delayed enhancement; delayed phase. **b** MRCP revealed obstruction of the MPD concordant with the tumors (*arrows*), and slight dilatation between the tumors (*arrowheads*). **c** On macroscopic examination, the cut surface of the tumors showed swelling of the parenchyma, and the border between the tumor and the surrounding pancreatic tissue was unclear. The parenchyma between the two lesions was markedly atrophic. The MPD was narrowed in the tumor lesions, but was normal in the area between the tumors (*arrows*). **d** Microscopic examination confirmed that the MPD was narrowed, with dense lymphoplasmacytic infiltration and severe periductal fibrosis around the MPD. **e** Lymphocytes and plasma cells around the MPD. *Inset* shows IgG4-positive plasma cells. **d** H&E, × 40; **e** H&E, × 200; *inset* in **e** IgG4 staining, × 400

(Fig. 2d, e). Lobular inflammation, atrophy of the parenchyma, and obliterative phlebitis were also observed. No cystic lesion or calcification was detected. On immunohistochemical staining, abundant plasma cells showing strong immunoreactivity for IgG4 were observed, predominantly around the pancreatic ducts (Fig. 2e, inset).

The parenchyma between the two lesions in case 2 was markedly atrophic, and the acinar cells were almost all replaced by fibrous tissue. The MPD was infiltrated with lymphoplasmacytes, including IgG4-positive plasma cells, as observed in the tumorous area.

The serum IgG4 level, measured postoperatively, was elevated in both patients (case 1, 149 mg/dl; case 2, 183 mg/dl [normal, 0–135 mg/dl[8]]).

Discussion

Since Yoshida et al.[1] proposed the term "autoimmune pancreatitis (AIP)" to describe a type of chronic pancreatitis with an autoimmune mechanism in 1995, the concept of AIP has been widely recognized. The characteristics of AIP are described as follows: mild symptoms, increased serum γ-globulin or IgG level and the presence of autoantibodies, diffuse enlargement of the pancreas, diffuse irregular narrowing of the MPD, fibrotic change with lymphoplasmacyte infiltration histopathologically, and a favorable response to steroid therapy.[1] In addition, an elevated concentration of serum IgG4 is reported to be supportive of the diagnosis of AIP.[8]

AIP is frequently associated with other autoimmune disorders such as inflammatory bowel disease and sclerosing cholangitis. Recently, IgG4-related sclerosing diseases of organs other than the pancreas have been documented.[9] Various organs, including the bile duct, gallbladder, salivary gland, and retroperitoneum are considered to be affected multifocally. These organs are characterized by dense infiltrations of IgG4-positive plasma cells.

With an increase of AIP cases being reported, some AIP patients have presented with focal involvement

showing localized narrowing of the MPD and focal swelling of the pancreas.[2–4] As this focal variant of AIP sometimes shows clinical and radiological findings resembling those of pancreatic carcinoma, patients with such findings have frequently been treated surgically for suspected malignancy.[6] Although some diagnostic clues have been reported to differentiate the focal type of AIP from pancreatic carcinoma, such as a fluctuating course of jaundice,[3] homogeneous delayed enhancement on dynamic CT, longer stenosed MPD without upstream dilatation,[4] and raised concentration of serum IgG4,[8] definite discrimination is still difficult in spite of the advances in imaging technology. Even with FDG-PET examination, when the lesion is localized, it can be confused with pancreatic malignancy, because it has been reported to show increased uptake at the affected site of AIP.[10]

Our preoperative diagnosis in both the present patients was pancreatic carcinoma with obstructive pancreatitis demonstrating mass lesions, or double primary pancreatic carcinomas. However, the possibility of mass-forming pancreatitis should have been entertained, considering the fact that cases of double pancreatic carcinomas have seldom been encountered in clinical settings and considering the finding that the tumor markers in both patients were within normal limits. From a retrospective point of view, stenotic or obstructive findings of the MPD on MRCP are not only characteristic of pancreatic carcinoma but may also be suggestive of AIP, because of the low resolution of MRCP.

Interestingly, the parenchyma between the two lesions in case 2, which appeared almost normal on radiological images, was markedly atrophic, and the acinar cells were almost all replaced by fibrosis on microscopic examination. The MPD was infiltrated with lymphoplasmacytes, including IgG4-positive plasma cells. This suggested that this area had suffered from autoimmune inflammation previously and was almost burned out. In other words, the intensity of inflammation may be related to the degree of swelling of the pancreas, and parenchyma that appears normal on radiological examination may be either actually normal or mildly affected without clinical manifestation, or it may already be burned out as in our case 2.

Considering a reported case of AIP that started as a localized form and progressed to diffuse swelling of the pancreas,[11] the focal type of AIP may be regarded as part of the same clinical spectrum as the diffuse type of AIP. Whether the distribution is diffuse or focal may merely reflect the stage or extent of the disease.[12]

The serum IgG4 level, measured postoperatively, was elevated in both of our patients. However, a case of pancreatic cancer in a patient with a high serum IgG4 concentration was recently reported.[13] Without definite criteria, it is still difficult to discriminate the focal type of AIP from pancreatic carcinoma. Therefore, it is clinically important to know that AIP sometimes exhibits multiple lesions within the pancreas.

References

1. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995;40:1561–8.
2. Sahani DV, Kalva SP, Farrell J, Maher MM, Saini S, Mueller PR, et al. Autoimmune pancreatitis: imaging features. Radiology 2004;233:345–52.
3. Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003;98:2694–9.
4. Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Okai T, et al. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003;98:2679–87.
5. Matsubara T, Sakurai Y, Miura H, Kobayashi H, Shoji M, Nakamura Y, et al. Complete obstruction of the lower common bile duct caused by autoimmune pancreatitis: is biliary reconstruction really necessary? J Hepatobiliary Pancreat Surg 2005;12:76–83.
6. Ajisaka H, Fujita H, Kaji M, Maeda K, Yabushita K, Konishi K, et al. Lymphoplasmacytic sclerosing pancreatocholangitis successfully treated by pancreatoduodenectomy. J Hepatobiliary Pancreat Surg 2002;9:522–6.
7. Ohana M, Okazaki K, Hajiro K, Kobashi Y. Multiple pancreatic masses associated with autoimmunity. Am J Gastroenterol 1998;93:99–102.
8. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732–8.
9. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006;41:613–25.
10. Nakamoto Y, Saga T, Ishimori T, Higashi T, Mamede M, Okazaki K, et al. FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med 2000;27:1835–8.
11. Koga Y, Yamaguchi K, Sugitani A, Chijiiwa K, Tanaka M. Autoimmune pancreatitis starting as a localized form. J Gastroenterol 2002;37:133–7.
12. Wakabayashi T, Kawaura Y, Satomura Y, Fujii T, Motoo Y, Okai T, et al. Clinical study of chronic pancreatitis with focal irregular narrowing of the main pancreatic duct and mass formation: comparison with chronic pancreatitis showing diffuse irregular narrowing of the main pancreatic duct. Pancreas 2002;25:283–9.
13. Kamisawa T, Chen PY, Tu Y, Nakajima H, Egawa N, Tsuruta K, et al. Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol 2006;12:6225–8.

Scandinavian Journal of Gastroenterology, 2008; 43: 110–116

informa
healthcare

ORIGINAL ARTICLE

Incidence of the focal type of autoimmune pancreatitis in chronic pancreatitis suspected to be pancreatic carcinoma: Experience of a single tertiary cancer center

MASATOSHI KAJIWARA[1], NAOTO GOTOHDA[1], MASARU KONISHI[1], TOSHIO NAKAGOHRI[1], SHINICHIRO TAKAHASHI[1], MOTOHIRO KOJIMA[2] & TAIRA KINOSHITA[1]

[1]*Department of Hepatobiliary Pancreatic Surgery and* [2]*Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan*

Abstract

Objective. With an increase in autoimmune pancreatitis (AIP) being reported, the focal type of AIP, which shows localized narrowing of the main pancreatic duct and focal swelling of the pancreas, has recently been recognized. Therefore, cases of focal-type AIP subjected to surgical intervention for presumptive malignancy might previously have been diagnosed as mass-forming chronic pancreatitis. The aim of this study was to elucidate the incidence of focal-type AIP in resected chronic pancreatitis at a single tertiary cancer center. The clinical and radiological features of focal-type AIP were also evaluated. ***Material and methods.*** We re-evaluated 15 patients who underwent pancreatic resection with a presumed diagnosis of pancreatic ductal adenocarcinoma, and who in the past had been diagnosed pathologically as having chronic pancreatitis. ***Results.*** Seven of 15 patients showed AIP, and the other 8 patients were diagnosed as having mass-forming chronic pancreatitis not otherwise specified by pathological retrospective examination. In other words, nearly half of the cases of resected chronic pancreatitis that were suspected to be pancreatic carcinoma preoperatively showed focal-type AIP. Regarding the characteristic findings of focal-type AIP, narrowing of the pancreatic duct on endoscopic retrograde pancreatography (ERP) might be diagnostic. ***Conclusions.*** Focal-type AIP is not a rare clinical entity and might be buried in previously resected pancreatic specimens that in the past were diagnosed simply as mass-forming pancreatitis.

Key Words: *Autoimmune pancreatitis, focal type, pancreatic carcinoma*

Introduction

Autoimmune pancreatitis (AIP) is a special type of chronic pancreatitis characterized by diffuse swelling of the pancreatic parenchyma and irregular narrowing of the pancreatic duct system, periductal lymphoplasmacytic infiltration and fibrosis, and a favorable response to steroid therapy [1].

With increasing recognition of AIP, however, AIP with focal involvement has recently been reported [2–7]. This focal type of AIP is considered to be in the same clinical category as the diffuse type of AIP, and only the extent of the disease may differ between them [8].

Regarding tertiary cancer centers, patients with so-called mass-forming chronic pancreatitis have been referred to our institute with a presumptive diagnosis of pancreatic ductal adenocarcinoma and subjected to surgical exploration. As focal-type AIP has not been well known in the clinical setting until only recently, patients with this category of disease who had received pancreatic resection for suspected malignancy might previously simply have been diagnosed with mass-forming chronic pancreatitis. Therefore, the frequency of focal-type AIP in patients with chronic pancreatitis who underwent surgical intervention has not been well documented.

Correspondence: Naoto Gotohda, Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. Tel: +81-4-7133-1111. Fax: +81-4-7131-4724. E-mail: ngotohda@east.ncc.go.jp

(Received 30 May 2007; accepted 19 June 2007)

ISSN 0036-5521 print/ISSN 1502-7708 online © 2008 Taylor & Francis
DOI: 10.1080/00365520701529238

In this study, we retrospectively reviewed all resected specimens of chronic pancreatitis for presumed pancreatic carcinoma, and uncovered the incidence of focal-type AIP in a single tertiary cancer center. Moreover, the clinical and radiological features of focal-type AIP were also evaluated.

Material and methods

From July 1992 to December 2006, 15 patients underwent surgical exploration with a presumptive diagnosis of pancreatic ductal adenocarcinoma, and were diagnosed pathologically as having chronic pancreatitis in the past. We re-evaluated the pathological specimens of these 15 patients, and classified them as AIP or mass-forming pancreatitis not otherwise specified.

The pathological characteristics of AIP are: dense periductal lymphoplasmacytic inflammation, periductal and parenchymal fibrosis, and obliterative venulitis [9]. In an immumohistochemical study, dense infiltration of IgG4-positive plasma cells was also reported to be diagnostic [10–12].

The clinical manifestations and radiological findings for focal-type AIP were also reviewed. Each patient received dynamic computed tomography (CT) and either endoscopic retrograde cholangiopancreatography (ERCP) (4 patients) or magnetic resonance cholangiopancreatography (MRCP) (3 patients).

Results

Incidence of focal-type AIP

Seven (all male) of 15 patients showed AIP, and the other 8 patients (7 M, 1 F) were diagnosed as having mass-forming chronic pancreatitis not otherwise specified, pathologically. Immunohistochemical staining for IgG4 was positive in all AIP patients except one, whereas it was negative in all patients with mass-forming pancreatitis.

Distribution and number of mass lesions

Of the 7 AIP patients, 5 showed a single mass lesion, including 4 in the pancreatic head and one in the body–tail of the pancreas. The remaining 2 patients showed double lesions within the pancreas; one patient with tumors in the pancreatic head and body underwent pancreaticoduodenectomy, and the other patient with mass lesions in the body and tail was subjected to distal pancreatectomy for suspected pancreatic carcinoma (Table I).

Table I. Clinical, laboratory and CT findings in seven patients with resected AIP.

Case	Age/gender	Past history	Symptoms	CEA (ng/ml)	CA19-9 (U/ml)	IgG4 (mg/dl)	Location	Size (mm)	Operation	Delayed enhancement	Capsule-like rim
1	64/M	None	None	0.9	6.2	183	Body, tail	28, 30	DP	++	–
2	62/M	HT	Epigastralgia	2.8	11.1	149	Head, body	30, 25	SSpPD	+	–
3	59/M	None	Epigastralgia, jaundice	0.9	8	NA	Head (Uncus)	30	SSpPD	+++	–
4	51/M	None	None	1.8	5	NA	Body-tail	50	DP	++	+
5	60/M	DM	Epigastralgia, jaundice	3.8	228	NA	Head	23	PpPD	++	–
6	62/M	None	Epigastralgia, jaundice	3.2	98	NA	Head	40	PpPD	+	–
7	68/M	Ulcer, gout	Jaundice	1.6	14	NA	Head	45	PpPD	+	–

Abbreviations: AIP = autoimmune pancreatitis; CEA = carcinoembryonic antigen; NA = not available; HT = hypertension; DM = diabetes mellitus; DP = distal pancreatectomy; SSpPD = subtotal stomach-preserving pancreaticoduodenectomy; PpPD = pylorus-preserving pancreaticoduodenectomy.

Back ground and clinical symptoms

All AIP patients were male and had no other autoimmune-related disorders or history of alcohol abuse. Their age range was 51–68 years, with a mean of 60.9 years. Abdominal symptoms were present in 4 cases; however, they were mild, with epigastric discomfort rather than pain. The other 3 patients had no abdominal symptoms (Table I).

A total of 5 patients had mass lesions in the head of the pancreas. Four patients presented with obstructive jaundice, but fluctuation of jaundice was not observed in any of the patients. The other patient with a pancreatic head mass did not show obstructive jaundice, although the tumor was large at 30 mm in diameter.

Laboratory data

Serum level of IgG4 was measured in only 2 patients with AIP, and was above the normal limit (normal range: 0–135 mg/dl [13]) in both of them. Regarding tumor markers, carcinoembryonic antigen (CEA) was within normal limits in all patients; however, carbohydrate antigen (CA) 19-9 was raised in 2 patients. Autoantibodies were not evaluated (Table I).

Dynamic CT images

Every patient showed a localized pancreatic lesion, and to some extent delayed enhancement in dynamic CT studies. The degree of mass formation varied from mild swelling of the parenchyma to a distinct tumor-like lesion. A capsule-like rim was identified in only one patient. Neither a cystic component nor calcification was detected (Table I, Figures 1 and 2).

Main pancreatic duct

Apart from the case involving the uncinate process with a normal main pancreatic duct (MPD), a duct in the area of the mass lesion was observed in the other 6 patients. Four patients who underwent endoscopic retrograde pancreatography (ERP) showed smooth or irregular narrowing of the MPD, whereas the two patients who recently received magnetic resonance pancreatography (MRP) demonstrated obstruction of the MPD in accordance with the tumor (Table II, Figures 3 and 4).

Post-stenotic dilatation of the MPD was observed in all patients with the exception of two; one of these patients had a tumor in the uncinate process and therefore showed normal pancreatic duct features, and the other had a mass located in the body–tail of the pancreas, so the post-stenotic status was not evaluated. However, post-stenotic dilatation was mild and the MPD had a maximum diameter of less than 5 mm in all patients.

Common bile duct

Stricture of the lower common bile duct was detected on endoscopic retrograde cholangiography (ERC) or magnetic resonance cholangiography (MRC) in all 5 patients with a pancreatic head lesion, including one patient without obstructive jaundice.

Findings of mass-forming pancreatitis

Clinical and radiological findings of chronic pancreatitis not otherwise specified were also reviewed (Table III). The mean age was 49.6 years and younger than that for patients with focal-type AIP.



Figure 1. Dynamic computed tomography (CT) in case 3 shows a distinct mass lesion in the head of the pancreas with delayed enhancement (*arrows*). (a) Arterial phase, (b) portal phase, (c) delayed phase.



Figure 2. Arterial phase, contrast-enhanced computed tomography (CT) in case 4 shows a mass-like lesion in the body to tail of the pancreas, with a low-attenuated capsule-like rim (*arrows*).



Figure 3. Endoscopic retrograde pancreatography (ERP) in case 6 shows segmental smooth narrowing of the main pancreatic duct (MPD) in the pancreatic head, with mild upstream dilatation (maximum diameter is 4 mm).

Three patients had a history of alcohol abuse. Although 7 out of 8 patients had lesions in the head of the pancreas, obstructive jaundice was observed in only 2 patients.

On dynamic CT examination, 5 patients showed delayed enhancement to some extent. Cystic lesions and calcification in the tumor, which were not observed in focal-type AIP, were detected in 3 patients and 1 patient, respectively. MPD stenosis on MRP was detected in 2 patients; at ERP, 4 out of 6 patients showed narrowing of the MPD, whereas the other 2 patients had normal MPD features.

Discussion

AIP is a unique entity of chronic pancreatitis, with an autoimmune etiological mechanism [1,14,15]. It is also known as lymphoplasmacytic sclerosing pancreatitis (LPSP) based on its characteristic pathological findings [9]. Clinically, obstructive jaundice is considered a major presenting symptom [16].

AIP usually affects the whole pancreas; however, a focal type of AIP, which affects a localized area of the pancreas and often exhibits mass formation, has been reported [2–7]. In fact, the diagnostic criteria for AIP proposed by the Japan Pancreas Society [17] were revised in 2006, and the description of the length of the affected pancreatic duct, which was previously defined as more than 1/3 the length of the entire pancreas, was abolished. If we consider AIP as starting as a local form that progresses to diffuse swelling of the pancreas [18], focal-type AIP can be regarded as part of the same clinical spectrum as the diffuse type of AIP. Whether the distribution is diffuse or focal merely reflects the stage or the extent of the disease [8].

This focal type of AIP has recently been recognized; therefore, there might be many cases of this clinical entity buried in pancreatic specimens that were resected for suspected pancreatic carcinoma and were diagnosed as mass-forming chronic pancreatitis in the past.

In the present study, out of 15 patients with chronic pancreatitis who underwent surgical exploration,

Table II. Radiological findings of MPD on MRP or ERP.

		MRP findings		ERP findings	
Case	Location	MPD	Post-stenotic dilatation	MPD	Post-stenotic dilatation
1	Body, tail	Stenosis	3 mm		
2	Head, body	Stenosis	4 mm		
3	Head (Uncus)	Normal	–		
4	Body–tail			Smooth narrowing	Not evaluated
5	Head			Irregular narrowing	4 mm
6	Head			Smooth narrowing	4 mm
7	Head			Irregular narrowing	5 mm

Abbreviations: MPD = main pancreatic duct; MRP = magnetic resonance pancreatography; ERP = endoscopic retrograde pancreatography.

Figure 4. Magnetic resonance pancreatography (MRP) in case 2 shows segmental obstructions of the main pancreatic duct in the area of the double tumors and mild post-stenotic dilatation. (*arrows*: head lesion; *arrow heads*: body lesion).

7 were shown to have AIP and the other 8 patients were diagnosed as having mass-forming pancreatitis not otherwise specified. The pathologic diagnosis of AIP was easily made based on characteristic findings such as dense periductal lymphoplasmacytic inflammation, parenchymal fibrosis, and obliterative venulitis on hematoxylin & eosin staining. With regard to immunohistochemical staining for IgG4, Zhang et al. [12] reported that the sensitivity in resected AIP specimens was 72% (21/29). In the present study, there was one IgG4-negative AIP case, so it was considered just to be a supportive clue in resected pancreatic specimens.

During the same period, in comparison, a total of 145 patients with pancreatic ductal adenocarcinoma received pancreatic resection (107 pancreaticoduodenectomies, 36 distal pancreatectomies, and 2 total pancreatectomies). In other words, 9.4% (15/160) of patients with presumed pancreatic carcinoma had benign pancreatitis. Moreover, nearly half the cases of mass-forming chronic pancreatitis were shown to be AIP. It is thus considered that the focal type of AIP is by no means a rare clinical entity.

The results of pancreaticoduodenectomy in some high volume centers in western countries have been reported, and similarly, about 10% (11–13%) of cases were shown to be benign disease [19–21]. These studies also reported an 11–34% incidence of focal-type AIP out of resected so-called chronic pancreatitis. These studies, however, were different from our report essentially in two points: the type of resection was limited to only pancreaticoduodenectomy, and the population included every peripancreatic disease and disorder. Although chronic mass-forming pancreatitis resembles pancreatic ductal adenocarcinoma clinically and radiologically, most periampullary tumors, pancreatic endocrine tumors, and pancreatic cystic tumors are easily diagnosed with their characteristic findings. Therefore, we excluded these tumors in the present study and calculated the incidence of the focal type of AIP.

Sasson et al. [20] also reported that despite the advances in imaging modalities, the ability to discriminate between benign inflammatory conditions and neoplastic disease is still inadequate. Similarly, in our institution the incidence of resected AIP has not decreased, even in recent years.

The clinical presentations and radiological findings of focal-type AIP are similar to those of pancreatic malignancy, especially ductal adenocarcinoma;

Table III. Clinical, radiological and pathological findings in both resected AIP and mass-forming pancreatitis not otherwise specified.

		Focal-type AIP ($n=7$)	Mass-forming pancreatitis NOS ($n=8$)
Age	Mean (range)	60.9 (51–68)	49.6 (38–74)
Gender	Male:Female	7:0	7:1
Background	Alcohol abuse	0/7	3/8
	Autoimmune history	0/7	0/8
	Etiology		Alcoholic: 3 Gallstones: 1 Not specified: 4
Location	Head	5/7	7/8
Symptoms	Jaundice*	4/5	2/7
	Epigastralgia	4/7	3/8
CT	Delayed enhancement	7/7	5/8
	Capsule-like rim	1/7	0/8
	Cyst	0/7	3/8
	Calcification	0/7	1/8
MRP	MPD stenosis	2/2	2/2
ERP	MPD narrowing	4/4	4/6
Pathology	IgG4(+) plasma cells	6/7	0/8

Abbreviations: NOS = not otherwise specified; AIP = autoimmune pancreatitis; CT = computed tomography; MRP = magnetic resonance pancreatography; ERP = endoscopic retrograde pancreatography.
*Patients with lesions of the pancreatic head.

therefore, some AIP patients have been treated surgically [22]. Regarding the favorable response of AIP to steroid therapy, accurate diagnosis is considered clinically important.

The characteristic features of pancreatic ductal adenocarcinoma have already been well documented and recognized. Jaundice, pain, and weight loss are its classic symptoms [23]. On dynamic CT, pancreatic ductal adenocarcinoma typically has the appearance of an ill-defined, hypoattenuating focal mass during the arterial phase when compared with the normal pancreatic parenchyma, along with diminished enhancement in the delayed phase [24,25]. Moreover, obstruction of the MPD on ERP is considered to be the most common pancreaticographic finding [25].

Recently, some characteristic findings of focal-type AIP have been reported to be useful in discriminating AIP from pancreatic carcinoma, such as the fluctuating course of jaundice [4], frequent association with other autoimmune disorders [1,10,11], raised serum levels of IgG4 [6,13], homogeneous delayed enhancement in dynamic CT, and longer MPD stenosis without upstream dilatation (maximum upstream diameter <6 mm) [5].

In the present study, 4 out of the 5 patients with pancreatic head lesions presented with obstructive jaundice, but fluctuation was not observed. In past medical history, there was no other autoimmune disease such as inflammatory bowel disease in any patient.

The serum level of IgG4, which was measured in only 2 patients, was raised. Although evaluation of serum IgG4 might be useful, it is not a definite diagnostic clue, as was recently reported in a case of pancreatic carcinoma with a high serum IgG4 concentration [26].

CT images showed delayed enhancement of the tumor to some extent in every patient. However, this finding indicates abundant fibrosis in the pancreatic parenchyma, which applies to both chronic pancreatitis and pancreatic ductal adenocarcinoma. Discrimination of these two entities according to the degree of enhancement is considered clinically impossible.

Irie et al. [27] reported that a capsule-like rim around the pancreas, reflecting the inflammatory process, was a typical sign of AIP. However, in the present study, only 1 out of 7 patients exhibited this feature in dynamic CT; therefore, a capsule-like rim might be less sensitive for the diagnosis of focal-type AIP.

To some extent post-stenotic dilatation of the MPD was detected in all patients with the exception of two; one had a tumor in the uncinate process, and the mass in the other patient was located in the body–tail of the pancreas; therefore, evaluation of the post-stenotic status was impossible. However, the maximal diameter was limited to within 5 mm in all patients as was previously reported [5].

Kamisawa et al. [28] reported the different appearance of MRP and ERP images in AIP patients; the narrowed portion of the MPD noticed on ERP was not visualized on MRP. Therefore, MRP cannot differentiate the irregular narrowing of the main pancreatic duct seen within AIP from stenosis of the MPD in pancreatic ductal adenocarcinoma.

Similarly, 4 patients who underwent ERP demonstrated irregular or smooth narrowing of the pancreatic duct; in contrast, 2 patients who recently underwent MRP exhibited obstruction of the MPD. Examination of the cut surface of the resected specimen in these two patients who underwent MRP confirmed that the narrowed MPD actually penetrated the tumor. Stenotic or obstructive findings of the MPD on MRP are not only characteristic of pancreatic carcinoma, but may be suggestive of AIP, because of the low resolution of MRP. Alternatively, ERP findings of AIP such as irregular or smooth narrowing of the pancreatic duct are considered to be diagnostic in order to differentiate AIP from pancreatic carcinoma.

In conclusion, about 10% of patients who were suspected of having pancreatic ductal adenocarcinoma and were subjected to surgical intervention had chronic pancreatitis in the clinical setting. Moreover, about half of the cases of resected chronic pancreatitis showed focal-type AIP. These findings suggest that the focal type of AIP is not a rare clinical entity, and undiagnosed cases might be buried in previously resected pancreatic specimens that in the past were diagnosed simply as mass-forming pancreatitis.

References

[1] Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995;40:1561–8.

[2] Kawamoto S, Siegelman SS, Hruban RH, Fishman EK. Lymphoplasmacytic sclerosing pancreatitis with obstructive jaundice: CT and pathology features. AJR Am J Roentgenol 2004;183:915–21.

[3] Sahani DV, Kalva SP, Farrell J, Maher MM, Saini S, Mueller PR, et al. Autoimmune pancreatitis: imaging features. Radiology 2004;233:345–52.

[4] Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003;98:2694–9.

[5] Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Okai T, et al. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or

mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003;98:2679–87.

[6] Hirano K, Komatsu Y, Yamamoto N, Nakai Y, Sasahira N, Toda N, et al. Pancreatic mass lesions associated with raised concentration of IgG4. Am J Gastroenterol 2004;99:2038–40.

[7] Weber SM, Cubukcu-Dimopulo O, Palesty JA, Suriawinata A, Klimstra D, Brennan MF, et al. Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg 2003;7:129–37.

[8] Wakabayashi T, Kawaura Y, Satomura Y, Fujii T, Motoo Y, Okai T, et al. Clinical study of chronic pancreatitis with focal irregular narrowing of the main pancreatic duct and mass formation: comparison with chronic pancreatitis showing diffuse irregular narrowing of the main pancreatic duct. Pancreas 2002;25:283–9.

[9] Klimstra DS, Adsay NV. Lymphoplasmacytic sclerosing (autoimmune) pancreatitis. Semin Diagn Pathol 2004;21: 237–46.

[10] Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006;41:613–25.

[11] Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 2004;28:1193–203.

[12] Zhang L, Notohara K, Levy MJ, Chari ST, Smyrk TC. IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. Mod Pathol 2007;20:23–8.

[13] Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344:732–8.

[14] Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas- an autonomous pancreatic disease? Am J Dig Dis 1961;6:688–98.

[15] Klöppel G, Lüttges J, Lohr M, Zamboni G, Longnecker D. Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas 2003;27:14–9.

[16] Matsubara T, Sakurai Y, Miura H, Kobayashi H, Shoji M, Nakamura Y, et al. Complete obstruction of the lower common bile duct caused by autoimmune pancreatitis: is biliary reconstruction really necessary? J Hepatobiliary Pancreat Surg 2005;12:76–83.

[17] Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Research Committee of Intractable Diseases of the Pancreas supported by the Japanese Ministry of Health, Labor and Welfare, and Members of the Autoimmune Pancreatitis Diagnostic Criteria Committee, the Japan Pancreas Society. Clinical diagnostic criteria of autoimmune pancreatitis 2006. J Jpn Pan Soc 2006;21:397.

[18] Koga Y, Yamaguchi K, Sugitani A, Chijiiwa K, Tanaka M. Autoimmune pancreatitis starting as a localized form. J Gastroenterol 2002;37:133–7.

[19] Abraham SC, Wilentz RE, Yeo CJ, Sohn TA, Cameron JL, Boitnott JK, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all "chronic pancreatitis"? Am J Surg Pathol 2003;27:110–20.

[20] Sasson AR, Gulizia JM, Galva A, Anderson J, Thompson J. Pancreaticoduodenectomy for suspected malignancy: have advancements in radiographic imaging improved results? Am J Surg 2006;192:888–93.

[21] Kennedy T, Preczewski L, Stocker SJ, Rao SM, Parsons WG, Wayne JD, et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg 2006;191:437–41.

[22] Ajisaka H, Fujita H, Kaji M, Maeda K, Yabushita K, Konishi K, et al. Lymphoplasmacytic sclerosing pancreatocholangitis successfully treated by pancreatoduodenectomy. J Hepatobiliary Pancreat Surg 2002;9:522–6.

[23] Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006;73:485–92.

[24] Faria SC, Tamm EP, Loyer EM, Szklaruk J, Choi H, Charnsangavej C. Diagnosis and staging of pancreatic tumors. Semin Roentgenol 2004;39:397–411.

[25] Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001;38: 105–12.

[26] Kamisawa T, Chen PY, Tu Y, Nakajima H, Egawa N, Tsuruta K, et al. Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol 2006;12:6225–8.

[27] Irie H, Honda H, Baba S, Kuroiwa T, Yoshimitsu K, Tajima T, et al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol 1998;170:1323–7.

[28] Kamisawa T, Chen PY, Tu Y, Nakajima H, Egawa N, Tsuruta K, et al. MRCP and MRI findings in 9 patients with autoimmune pancreatitis. World J Gastroentrol 2006;12: 2919–22.

Human Pathology (2008) 39, 37–48

ELSEVIER

Human PATHOLOGY

www.elsevier.com/locate/humpath

Original contribution

Primary tumor/vessel tumor/nodal tumor classification of extrahepatic bile duct carcinoma☆

Takahiro Hasebe MD, PhD[a,b,*], Masaru Konishi MD[c], Motoki Iwasaki MD, PhD[d], Toshio Nakagohri MD, PhD[c], Shin-ichiroh Takahashi MD, PhD[c], Naoto Gotohda MD, PhD[c], Taira Kinoshita MD, PhD[c], Atsushi Ochiai MD, PhD[e]

[a]*Surgical Pathology Section, Clinical Laboratory Division, National Cancer Center Hospital East, Kashiwa, Chiba, 277-0882, Japan*
[b]*Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, 104-0045, Japan*
[c]*Department of Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, 277-0882, Japan*
[d]*Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tsukiji, Tokyo, 104-0045, Japan*
[e]*Pathology Division, Innovative Medical Research Center, National Cancer Center, Kashiwa, Chiba, 277-0882, Japan*

Received 30 November 2006; revised 27 April 2007; accepted 1 May 2007

Keywords:
Extrahepatic bile duct carcinoma;
Prognosis;
Vessel;
Lymph node;
Stromal cell

Summary Although the pathological tumor-node-metastasis (pTNM) classification is the histologic prognostic classification currently used clinically worldwide to predict the outcome of patients with extrahepatic bile duct carcinoma (EBDC), some patients with EBDC in the early pTNM stage experience tumor recurrence and some of them die of their disease. We have confirmed that the histologic characteristics of tumor cells and tumor stromal cells in the vessels and lymph nodes of patients with EBDC are more strongly associated with tumor recurrence or death than in the primary tumor. The purpose of this study was to establish a primary tumor/vessel tumor/nodal tumor (PVN) classification for EBDC that would accurately predict the outcome of 72 patients. Multivariate analyses using the Cox proportional hazard regression model were used to compare the ability of the PVN classification to predict tumor recurrence and death with that of the pTNM, the American Joint Committee on Cancer, and the Japanese pTNM classification systems; and the results showed that only the PVN classification significantly increased the hazard rates for tumor recurrence and death independent of nodal status ($P < .05$). We conclude that the PVN classification is *probably* the most accurate prognostic classification system available for EBDC.

1. Introduction

Extrahepatic bile duct carcinoma (EBDC) is a fatal disease, and that has made it difficult to conduct a study that would accurately identify prognostic histologic parameters.

☆ This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare and by a Grant-in-Aid for the Second Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare of Japan (Tokyo, Japan).
* Corresponding author. Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan.
E-mail address: thasebe@ncc.go.jp (T. Hasebe).

0046-8177/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.humpath.2007.05.002